Additional file 1: of XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance

Figure S1. Colony formation in shCon or shXLF cells treated with DMSO, cisplatin, cisplatin + L189 (LIG4 inhibitor), oxaliplatin, or oxaliplatin + L189, respectively. Figure S2. Genomic alteration frequency of core factors of NHEJ pathway (XLF, XRCC4, XRCC5, XRCC6, LIG4, PRKDC, TP53BP1, and DCLRE1C) was generated using cBioPortal [ http://www.cbioportal.org ] from database of TCGA (193 patients) and AMC (231 patients). Tumor types are indicated at the bottom and ordered by the frequency of samples harboring mutation, deletion, amplification and multiple alterations. Overall alteration frequency in liver cancer was highlighted. Figure S3. RNA-sequencing data organization of NHEJ pathway genes (XLF, XRCC4, XRCC5, XRCC6, LIG4, PRKDC, TP53BP1, and DCLRE1C) by TCGA to show frequency of NHEJ pathway gene amplification, gene expression, missense or truncating mutations. (ZIP 1521Â kb)

补充图S1：分别经二甲基亚砜（DMSO）、顺铂、顺铂+L189（LIG4抑制剂）、奥沙利铂、奥沙利铂+L189处理的转染对照短发夹RNA（shCon）的细胞与转染靶向XLF的短发夹RNA（shXLF）的细胞的集落形成情况。
补充图S2：非同源末端连接（Non-Homologous End Joining, NHEJ）通路核心因子（XLF、XRCC4、XRCC5、XRCC6、LIG4、PRKDC、TP53BP1及DCLRE1C）的基因组变异频率，通过cBioPortal平台[http://www.cbioportal.org] 从癌症基因组图谱（The Cancer Genome Atlas, TCGA，193例患者）与AMC（231例患者）数据库中提取生成。肿瘤类型标注于图底部，并按携带突变、缺失、扩增及多重变异的样本频率进行排序。肝癌的总体变异频率已做高亮标注。
补充图S3：基于TCGA数据库的NHEJ通路基因（XLF、XRCC4、XRCC5、XRCC6、LIG4、PRKDC、TP53BP1及DCLRE1C）的RNA测序数据整理结果，用于展示该通路基因的扩增、基因表达、错义突变或截短突变的发生频率。（ZIP压缩文件，大小1521 KB）